FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3204394629> ?p ?o ?g. }

• W3204394629 endingPage "e212" @default.
• W3204394629 startingPage "e206" @default.
• W3204394629 abstract "Introduction/Background The AML-Score has been validated in patients receiving traditional induction chemotherapies but not CPX-351. We conducted a retrospective analysis to evaluate, among patients with secondary acute myeloid leukemia who received intensive induction with CPX-351, if the AML-Score associates with (1) complete remission (CR) and (2) early mortality (EM) within 60 days of induction. Materials and Methods We abstracted demographic and clinical data from consecutive patients receiving CPX-351 at Sidney Kimmel Cancer Center at Thomas Jefferson University Hospital between September 2017 and November 2020. We used descriptive statistics and receiver operating curves to evaluate the relationship between AML-Score and rates of CR and EM. Results In total, 40 patients were included. 27 (67.5%) were male, 27 (67.5%) were white, 36 (90.0%) were not Hispanic or Latino, and 29 (72.5%) were aged ≥60 years. Twenty-seven patients (67.5%) had a CR, and 4 (10%) experienced EM. Observed rates of CR and EM generally increased with increasing predicted risk. The area under the curve was 0.75 (95% CI 0.60-0.90) for CR and 0.82 (95% CI 0.68-0.96) for EM. Conclusion The AML-Score tool trends in the correct direction for predicting CR and EM, and thus may facilitate oncologist prognostication and treatment planning for patients receiving CPX-351. However, its clinical utility is limited by its underestimation of the risk of CR and overestimation of the risk of EM. Further validation in a larger cohort is needed to calculate accurate point estimates of CR and EM risk in this population." @default.
• W3204394629 created "2021-10-11" @default.
• W3204394629 creator A5042291174 @default.
• W3204394629 creator A5069144526 @default.
• W3204394629 creator A5080406420 @default.
• W3204394629 date "2022-03-01" @default.
• W3204394629 modified "2023-09-30" @default.
• W3204394629 title "Validation of AML-score in Older Adults Receiving CPX-351 Intensive Induction Chemotherapy for Treatment of Secondary Acute Myeloid Leukemia" @default.
• W3204394629 cites W1556454749 @default.
• W3204394629 cites W1603494485 @default.
• W3204394629 cites W2006617902 @default.
• W3204394629 cites W2065464763 @default.
• W3204394629 cites W2090715900 @default.
• W3204394629 cites W2093274439 @default.
• W3204394629 cites W2114942826 @default.
• W3204394629 cites W2116298760 @default.
• W3204394629 cites W2124110638 @default.
• W3204394629 cites W2142514031 @default.
• W3204394629 cites W2147010550 @default.
• W3204394629 cites W2166525128 @default.
• W3204394629 cites W2339658711 @default.
• W3204394629 cites W2560012305 @default.
• W3204394629 cites W2751152093 @default.
• W3204394629 cites W2883399820 @default.
• W3204394629 cites W2905340197 @default.
• W3204394629 cites W2912054581 @default.
• W3204394629 cites W2944434778 @default.
• W3204394629 cites W2946564370 @default.
• W3204394629 cites W2991619365 @default.
• W3204394629 cites W2998792962 @default.
• W3204394629 cites W3028877880 @default.
• W3204394629 doi "https://doi.org/10.1016/j.clml.2021.09.016" @default.
• W3204394629 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34686446" @default.
• W3204394629 hasPublicationYear "2022" @default.
• W3204394629 type Work @default.
• W3204394629 sameAs 3204394629 @default.
• W3204394629 citedByCount "0" @default.
• W3204394629 crossrefType "journal-article" @default.
• W3204394629 hasAuthorship W3204394629A5042291174 @default.
• W3204394629 hasAuthorship W3204394629A5069144526 @default.
• W3204394629 hasAuthorship W3204394629A5080406420 @default.
• W3204394629 hasConcept C121608353 @default.
• W3204394629 hasConcept C126322002 @default.
• W3204394629 hasConcept C143998085 @default.
• W3204394629 hasConcept C167135981 @default.
• W3204394629 hasConcept C2776611710 @default.
• W3204394629 hasConcept C2776694085 @default.
• W3204394629 hasConcept C2778729363 @default.
• W3204394629 hasConcept C58471807 @default.
• W3204394629 hasConcept C71924100 @default.
• W3204394629 hasConcept C72563966 @default.
• W3204394629 hasConcept C76318530 @default.
• W3204394629 hasConceptScore W3204394629C121608353 @default.
• W3204394629 hasConceptScore W3204394629C126322002 @default.
• W3204394629 hasConceptScore W3204394629C143998085 @default.
• W3204394629 hasConceptScore W3204394629C167135981 @default.
• W3204394629 hasConceptScore W3204394629C2776611710 @default.
• W3204394629 hasConceptScore W3204394629C2776694085 @default.
• W3204394629 hasConceptScore W3204394629C2778729363 @default.
• W3204394629 hasConceptScore W3204394629C58471807 @default.
• W3204394629 hasConceptScore W3204394629C71924100 @default.
• W3204394629 hasConceptScore W3204394629C72563966 @default.
• W3204394629 hasConceptScore W3204394629C76318530 @default.
• W3204394629 hasIssue "3" @default.
• W3204394629 hasLocation W32043946291 @default.
• W3204394629 hasLocation W32043946292 @default.
• W3204394629 hasOpenAccess W3204394629 @default.
• W3204394629 hasPrimaryLocation W32043946291 @default.
• W3204394629 hasRelatedWork W1999020667 @default.
• W3204394629 hasRelatedWork W2050400868 @default.
• W3204394629 hasRelatedWork W2188913058 @default.
• W3204394629 hasRelatedWork W2406230970 @default.
• W3204394629 hasRelatedWork W2407255173 @default.
• W3204394629 hasRelatedWork W2809998966 @default.
• W3204394629 hasRelatedWork W2954897945 @default.
• W3204394629 hasRelatedWork W3018911986 @default.
• W3204394629 hasRelatedWork W3030916261 @default.
• W3204394629 hasRelatedWork W3144115443 @default.
• W3204394629 hasVolume "22" @default.
• W3204394629 isParatext "false" @default.
• W3204394629 isRetracted "false" @default.
• W3204394629 magId "3204394629" @default.
• W3204394629 workType "article" @default.